CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 84 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,381,274 | +8.6% | 46,445 | -34.2% | 0.00% | 0.0% |
| Q2 2023 | $1,272,032 | +121.2% | 70,590 | +124.7% | 0.00% | 0.0% |
| Q4 2022 | $574,931 | -21.2% | 31,417 | -15.4% | 0.00% | 0.0% |
| Q3 2022 | $730,000 | +39.8% | 37,155 | +32.7% | 0.00% | 0.0% |
| Q2 2022 | $522,000 | +58.2% | 27,993 | +86.4% | 0.00% | – |
| Q1 2022 | $330,000 | -82.6% | 15,021 | -77.5% | 0.00% | -100.0% |
| Q4 2021 | $1,897,000 | +114.1% | 66,782 | +58.6% | 0.00% | +100.0% |
| Q3 2021 | $886,000 | +50.4% | 42,095 | +34.8% | 0.00% | 0.0% |
| Q2 2021 | $589,000 | +131.0% | 31,232 | +114.2% | 0.00% | – |
| Q2 2020 | $255,000 | – | 14,581 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 623,819 | $11,336,501 | 9.41% |
| Finepoint Capital LP | 822,745 | $15,056 | 4.87% |
| Bain Capital Life Sciences Investors, LLC | 2,305,558 | $42,192 | 4.72% |
| Opaleye Management Inc. | 732,000 | $13,395,600 | 4.66% |
| 5AM Venture Management, LLC | 862,286 | $15,779,834 | 4.24% |
| SPHERA FUNDS MANAGEMENT LTD. | 671,644 | $12,291,085 | 2.64% |
| First Light Asset Management, LLC | 1,329,313 | $24,326,428 | 2.26% |
| BRAIDWELL LP | 3,469,674 | $63,495,034 | 2.13% |
| BVF INC/IL | 2,736,613 | $50,080,018 | 2.11% |
| Perceptive Advisors | 4,039,276 | $73,918,751 | 2.08% |